The Legal 500

Twitter Logo Youtube Circle Icon LinkedIn Icon

Slaughter and May

Living Wage
Work 020 7600 1200
Fax 020 7090 5000
Beijing, Brussels, Hong Kong, London

David Johnson

Work 020 7600 1200
Slaughter and May

Work Department



Partner specialising in corporate finance, commercial, general corporate and mergers and acquisitions; particular experience in public and private M&A transactions and equity financings.


Trained Slaughter and May; qualified 1993; partner 2000.


Nottingham High School; Trinity Hall, Cambridge (Law).

London: Corporate and commercial

Equity capital markets

Within: Equity capital markets

Known for its excellent client base and high-value mandates,¬†Slaughter and May's 'hugely responsive, extremely commercial' team 'takes complex problems, devours them and produces an answer'. It primarily advises issuers on equity capital markets matters, from germination to IPOs and post-listing work. Real estate, financial services and oil and gas have been especially busy sectors recently;¬†Susannah Macknay¬†and¬†Jeff Twentyman¬†acted for Glenveagh Properties on its ¬£550m IPO on the ISE and the LSE, and Macknay ‚Äď along with¬†Steven Galbraith¬†and¬†Richard Smith ‚Äď assisted Kosmos Energy with its secondary listing on the LSE.¬†David Johnson¬†is 'brilliant for straightforward, pithy advice'; he and the 'focused, upbeat'¬†Sally Wokes¬†acted for Segro on a ¬£573m rights issuance. Other clients of the 'exceptionally good' practice¬†include Ultra Electronics Holdings, Atlas Mara and HomeServe. The 'bright, incisive'¬†Nilufer Von Bismarck¬†heads the department.

[back to top]

M&A: upper mid-market and premium deals, £250m+

Within: Leading individuals

David Johnson - Slaughter and May

Within: M&A: upper mid-market and premium deals, £250m+

The ‚Äėvery high-quality‚Äô practice at¬†Slaughter and May¬†is¬†‚Äėdefinitely the go-to for large-scale and complex transactions‚Äô. The firm‚Äôs blue-chip client list includes Burberry, Diageo, General Electric, GlaxoSmithKline and Rolls-Royce. The M&A offering is headed by¬†Roland Turnill, while¬†Andy Ryde¬†leads the team‚Äôs broader corporate practice. Turnill and¬†Jonathan Marks¬†acted for Standard Life on its all-share merger with Aberdeen Asset Management, effected by court-sanctioned scheme of arrangement, and Turnill also advised Vodafone on the proposed merger of its India business with Idea Cellular.¬†Simon Nicholls¬†advised John Wood Group on its all-share offer for Amec Foster Wheeler and worked alongside¬†David Johnson¬†(recommended by one individual as ‚Äėsimply the best M&A lawyer I have ever worked with‚Äô) on Actelion‚Äôs $30bn takeover by Johnson & Johnson. Johnson also¬†acted on Cineworld Group‚Äôs $5.8bn acquisition of Regal Entertainment Group, while¬†Hywel Davies¬†led a large team handling INEOS‚Äô acquisition of the entire oil and gas business of DONG Energy, and senior partner¬†Steve Cooke¬†handled WS Atkins‚Äô ¬£2.1bn acquisition of SNC-Lavalin.¬†Nigel Boardman¬†and¬†William Underhill¬†remain involved with a wide variety of transactions and advisory matters.¬†Christian Boney¬†and¬†Filippo De Falco¬†were both promoted to partnership.¬†Chris McGaffin¬†moved to the firm's Hong Kong office in August 2017 and¬†Padraig Cronin¬†moved to the firm's pensions and employment practice. Gary Eaborn¬†retired.

[back to top]

London: TMT (technology, media and telecoms)

Pharmaceuticals and biotechnology

Within: Pharmaceuticals and biotechnology

Corporate, commercial, transactions and IP are the core areas of focus for Slaughter and May. Susie Middlemiss co-heads the team and has expertise in disputes and IP work. Fellow practice head David Johnson focuses on corporate and commercial transactions and assisted GlaxoSmithKline with the $619m sale of its 6.2% stake in Aspen Pharmacare. Alongside Johnson, corporate transactions expert Simon Nicholls worked with Actelion on its sale to Johnson & Johnson. Corporate and commercial law specialist Richard Smith advised Immunocore on its collaboration with the Bill & Melinda Gates Foundation, which will focus on developing treatments for HIV and TB using T-cell receptors.

[back to top]

Back to index

Legal Developments in London

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to